TINF2 is a haploinsufficient tumor suppressor that limits telomere length

Isabelle Schmutz¹, Arjen R Mensenkamp², Kaori K Takai¹, Maaike Haadsma², Liesbeth Spruijt², Richarda M de Voer², Seunga Sara Choo³, Franziska K Lorbeer³, Emma J van Grinsven³, Dirk Hockemeyer³,⁴, Marjolijn CJ Jongmans²*, Titia de Lange¹*

¹Laboratory for Cell Biology and Genetics, Rockefeller University, New York, United States; ²Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; ³Department of Molecular and Cellular Biology, University of California, Berkeley, Berkeley, United States; ⁴Chan Zuckerberg Biohub, San Francisco, United States

Abstract Telomere shortening is a presumed tumor suppressor pathway that imposes a proliferative barrier (the Hayflick limit) during tumorigenesis. This model predicts that excessively long somatic telomeres predispose to cancer. Here, we describe cancer-prone families with two unique TINF2 mutations that truncate TIN2, a shelterin subunit that controls telomere length. Patient lymphocyte telomeres were unusually long. We show that the truncated TIN2 proteins do not localize to telomeres, suggesting that the mutations create loss-of-function alleles. Heterozygous knock-in of the mutations or deletion of one copy of TINF2 resulted in excessive telomere elongation in clonal lines, indicating that TINF2 is haploinsufficient for telomere length control. In contrast, telomere protection and genome stability were maintained in all heterozygous clones. The data establish that the TINF2 truncations predispose to a tumor syndrome. We conclude that TINF2 acts as a haploinsufficient tumor suppressor that limits telomere length to ensure a timely Hayflick limit.

Introduction The idea that telomere attrition could repress the outgrowth of early stage cancer originates from the observation that telomeres shorten in normal human cells (Harley et al., 1990; Hastie et al., 1990; de Lange et al., 1990; reviewed in Maciejowski and de Lange, 2017). In agreement with this theory, telomere shortening leads to a proliferative barrier in vitro (the Hayflick limit Shay and Wright, 2000) that can be overcome when telomerase is activated through expression of hTERT Bodnar et al., 1998; telomerase activity is required to create tumorigenic derivatives from normal human cells Hahn et al., 1999; and telomerase activation is a hallmark of human cancer (Shay and Bacchetti, 1997). The discovery of hTERT promoter mutations in familial melanoma and other tumor types further solidified the view that telomere attrition is a barrier to tumorigenesis (Horn et al., 2013; Huang et al., 2013; reviewed in Lorbeer and Hockemeyer, 2020).

For the telomere tumor suppression pathway to limit cancer incidence, telomeres need to shorten at the correct rate, which in most primary human cells is ~30–100 bp/end/cell division (Harley et al., 1990; Huffman et al., 2000). The number of cell divisions a transformed clone can execute before proliferation is curbed by one or more critically short telomeres depends on the initial telomere length. Most likely, it is the lengths of the shortest telomeres in a clone that determine its proliferative potential (Hemann et al., 2001; Zou et al., 2004). These considerations predict that excessive telomere length at birth will delay the Hayflick limit and create a permissive state for cancer development. Indeed, after removal of telomerase, a cancer cell line with very long telomeres remained...
tumorigenic until its telomere reserve was depleted (Taboski et al., 2012). At birth, human telomeres have an average length that is specific to our species (Kipling and Cooke, 1990; Gomes et al., 2011). It is thought that this telomere reserve is sufficient to sustain the cell division needed for normal development and tissue homeostasis but becomes depleted during the over-proliferation associated with tumorigenesis. When and how human telomere length homeostasis is achieved has been difficult to discern.

In telomerase-positive tissue culture cells, telomere length homeostasis is mediated by shelterin (reviewed in Hockemeyer and Collins, 2015). TIN2 is a central component in shelterin that binds to three other shelterin subunits. TIN2 interacts with both double-stranded telomeric DNA-binding proteins – TRF1 and TRF2 – and binds TPP1, which forms a heterodimer with the single-stranded telomeric DNA-binding protein POT1 (reviewed in de Lange, 2018). TIN2 has been implicated as a negative regulator of telomere length as have TRF1 and POT1 (van Steensel and de Lange, 1997; Kim et al., 1999; Loayza and De Lange, 2003). The current model for telomere length homeostasis invokes a negative feedback loop, wherein telomerase is inhibited in cis by proteins (e.g. TRF1, TIN2, and POT1) that accumulate on the TTAGGG repeats synthesized by the enzyme.

It is well established that when telomeres are too short at birth, a devastating bone-marrow failure syndrome (dyskeratosis congenita [DC] and related syndromes) can arise. Missense mutations in a short stretch of amino acids of TIN2 (the DC patch) are responsible for ~25% of DC cases (Savage et al., 2008; Walne et al., 2008; reviewed in Savage and Bertuch, 2010), whereas the majority of DC cases are due to mutations impinging on telomerase biogenesis and activity.

Recent data on cancer-associated mutations in POT1 have provided a hint that long telomeres may predispose to cancer. Inherited POT1 mutations in cancer-prone families are associated with excessively long telomeres in somatic cells (Robles-Espinoza et al., 2014; NCI DCEG Cancer Sequencing Working Group et al., 2014; reviewed in Gong et al., 2020). However, the POT1 mutations also lead to genome instability, which has been invoked as the main pathogenic determinant (Ramsay et al., 2013; Pinzaru et al., 2016; Chen et al., 2017; Gu et al., 2017). Therefore, the POT1 mutations have not provided unambiguous evidence for the idea that long telomeres predispose to cancer.

Here, we describe heterozygous loss-of-function mutations in TINF2 in cancer-prone families. These mutations do not compromise telomere protection but create excessively long telomeres in vitro and in vivo. We conclude that the affected individuals are cancer-prone because their overly long telomeres thwart the telomere tumor suppressor pathway.

## Results

### Germline TINF2 mutations in families with cancer

In a routine diagnostic setting, whole-exome sequencing was performed on lymphocyte DNA of patients who developed multiple malignancies and/or had a striking family history of cancer. Germline variants in exon 5 of TINF2 (encoding TIN2) were discovered in four probands (Figure 1A–C; Figure 1—figure supplement 1). Three probands shared c.604G > C, whereas the fourth carried c.557del. The six individuals in this study developed 14 malignancies (Figure 1A), including three papillary thyroid carcinomas, three breast carcinomas, and two melanomas (Figure 1A). No loss of heterozygosity was detected in six tumors tested and second hits in TINF2 were excluded in four of the six tumors analyzed by whole-exome sequencing (F3:III-1: Astrocytoma, F2:II-1: Melanoma and breast cancer, F1:II-4: colorectal cancer (CRC), see also Figure 1—figure supplement 2). Multiple somatic driver mutations were identified, all previously associated with the tumor type in which the mutation was identified, such as BRAF (c.1799T > A, p.Val600Glu) in CRC and melanoma, and PIK3CA (c.1624G > A, p.Glu542Lys) in breast cancer (Figure 1—figure supplement 2). The tumors did not reveal a shared somatic mutational spectrum (data not shown). Based on these families, we suggest that carriers of the reported TINF2 variants might benefit from regular thyroid and dermatological surveillance as well as more general cancer surveillance.

Both TINF2 mutations generated truncated proteins (Figure 2). The c.557del mutation creates a shift in the reading frame after serine 186 that ends in a stop codon 23 amino acids downstream (p. (Ser186fs); Figure 2D). The c.604G > C change disrupts the splice donor site of exon 5 (Figure 2A, B). Transcript analysis showed that in addition to the wild-type full-length transcript...
and a transcript lacking exons 4 and 5 (ENST00000626689.2), patient samples contain an alternative transcript (604G > C II, Figure 2A,B). Transcript c.604G > C II lacks exon 5 and contains 20 extra nucleotides from intron 4. It appears to arise from an alternative splice donor site in intron four with a good splice site consensus score (alt D4; Figure 2B,C). This transcript was also observed in heterozygous RPE1 cells carrying the c.604G > C change (see below). In addition, the +/c.604G > C RPE1 cells contained a second allele-specific transcript (c.604G > C I, Figure 2B) generated through an alternative donor site in intron five that bears a good splice site consensus sequence (alt D5; Figure 2B,C and see Figure 4—figure supplement 1 below). The use of alt D5 results in the addition of 17 nucleotides from intron 5 (Figure 2B). This transcript was most likely missed in the analysis of the patient samples due to its lower abundance and co-migration with the wild-type full-length transcript. The c.604G > C I and c.604G > C II transcripts both have a frameshift in the TIN2 ORF and are predicted to encode truncated proteins (p.(L170fs) and p.(E202fs)) (Figure 2D).

Figure 1. Germline mutations in TINF2 identified in individuals with multiple malignancies. (A) TINF2 mutations and clinical features of affected individuals in four different families. Telomere length percentile is based on FlowFISH data (see below Figure 5—figure supplement 1A). (B, C) Pedigrees of one of the c.604G > C families (B) and the c.557del family (C) listed in (A). Probands are highlighted by arrows. Filled symbols indicate patients with confirmed TINF2 mutations and their clinical features are indicated. Symbols with vertical lines denote individuals who have developed cancer but have not been tested for TINF2 mutations. +: TINF2 mutation; -: wild type for TINF2; ?: not tested. See also Figure 1—figure supplement 1.

The online version of this article includes the following figure supplement(s) for figure 1:

Figure supplement 1. Pedigrees of two c.604G > C TINF2 families.

Figure supplement 2. Somatic mutations in the COSMIC cancer gene census identified in malignancies in TINF2 mutation carriers.

(ENST00000399423.8) and a transcript lacking exons 4 and 5 (ENST00000626689.2), patient samples contain an alternative transcript (604G > C II, Figure 2A,B). Transcript c.604G > C II lacks exon 5 and contains 20 extra nucleotides from intron 4. It appears to arise from an alternative splice donor site in intron four with a good splice site consensus score (alt D4; Figure 2B,C). This transcript was also observed in heterozygous RPE1 cells carrying the c.604G > C change (see below). In addition, the +/c.604G > C RPE1 cells contained a second allele-specific transcript (c.604G > C I, Figure 2B) generated through an alternative donor site in intron five that bears a good splice site consensus sequence (alt D5; Figure 2B,C and see Figure 4—figure supplement 1 below). The use of alt D5 results in the addition of 17 nucleotides from intron 5 (Figure 2B). This transcript was most likely missed in the analysis of the patient samples due to its lower abundance and co-migration with the wild-type full-length transcript. The c.604G > C I and c.604G > C II transcripts both have a frameshift in the TIN2 ORF and are predicted to encode truncated proteins (p.(L170fs) and p.(E202fs)) (Figure 2D).
Truncated versions of TIN2 do not bind TRF1 and do not localize to telomeres

The predicted truncated TIN2 proteins contain most of the N-terminal TRF homology (TRFH) domain of TIN2 where TRF2 and TPP1 bind and lack the TRF1-binding site and the short patch of amino acids mutated in dyskeratosis congenita (DC patch Savage et al., 2008; Walne et al., 2008; Figure 2D,E). To determine whether the truncated TIN2 proteins retain interactions with

Figure 2. Molecular analysis of transcripts resulting from TINF2 mutations. (A) Transcript analysis in peripheral blood lymphocytes (with and without cycloheximide treatment, CHX) from patients with the c.604G > C TINF2 mutation (F1:III-3 and F1:II-4; see Figure 1A) and a control individual. RT-PCR products were analyzed by Sanger sequencing. Wild-type full-length TIN2 mRNA, an alternative splice form found in wild-type cells (alt. splice exons 3–6) and mutant allele transcripts (604G > C I and 604G > C II) are indicated. Transcript 604G > C I was identified in heterozygous c.604G > C and homozygous c.604G > C RPE1 cells. (B) Schematic showing the splicing of exons 3–6 for full-length wild-type TINF2, the alternative splice variant (exons 3–6), and the aberrant splicing occurring in cells with c.604G > C mutations. Alt D4 and alt D5 indicate alternative splice donor sites. (C) Comparison of the consensus score of alternative splice donor sites alt D4 and alt D5 to splice donors D4 and D5 (as calculated by Human Splicing Finder www.umd.be). (D) Schematic of wild-type TIN2, and the predicted truncations resulting from expression of c.557del p.(S186fs), c.604G > C I p.(E202fs), and c.604G > C II p.(L170fs). Exon boundaries and the regions involved in TIN2 interactions with TRF1, TRF2, and TPP1 and the DC patch are indicated. (E) Structure of the TIN2 TRFH domain (PDB ID: 5xyf; Hu et al., 2017) with the amino acids at the truncation points highlighted. Peptides from TPP1 and TRF2 that interact with the TRFH domain are shown in the structure.
TIN2’s binding partners in shelterin, we generated expression constructs for the three predicted TIN2 truncations: L170fs and E202fs from c.604G > C and S186fs from c.557del. Co-immunoprecipitation from 293T cells co-transfected with HA-tagged TIN2 versions and myc-tagged TRF1 showed that, as expected, the truncated forms of TIN2 had lost the ability to bind to TRF1 (Figure 3A,B). The interaction with TRF2 was preserved in the c.604G > C derived E202fs truncation and was apparently enhanced in the c.557del-derived S186fs truncation (Figure 3A,B). In contrast, the c.604G > C L170fs protein showed very little (or no) interaction with TRF2 (Figure 3A,B). The

**Figure 3.** Truncated TIN2 versions show altered binding to shelterin subunits and diminished telomeric localization. (A) Co-immunoprecipitation of myc-tagged TRF1 (left panel), TRF2 (middle panel) and TPP1 (right panel) from 293T cells co-transfected with HA-tagged wt TIN2, S186fs, L170fs, E202fs, or the empty vector. Inputs and HA-IPs were probed with HA antibody to detect TIN2 and with myc antibody to detect TRF1, TRF2, and TPP1. To achieve equal expression levels, the ratio of plasmids was: wt 1x, 186fs 2.5x, 202fs 2.5x, and 170fs 5x. This experiment was repeated three times with comparable results. (B) Summary of the interaction of wild type and mutant TIN2 alleles with TRF1, TRF2, or TPP1 as derived from multiple co-IP experiments as in (A). (C) Immunoblot showing expression of HA-tagged wild type and mutant TIN2 versions in 293T cells used for telomeric ChIP. (D) Dot blot assay for telomeric ChIP performed on the indicated 293T cells as shown in (C). (E) Quantification of telomeric DNA recovered with HA Ab (average relative % telomeric DNA recovered in three independent experiments, individual data points and means ± SD are shown). For the quantification, unpaired t-test was used to determine significance, p-values: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns, not significant.
interaction with TPP1 was preserved in the E202fs version of TIN2 but not in the two other truncated forms (Figure 3A,B).

Since the localization of TIN2 to telomeres is primarily determined by its ability to interact with TRF1 (Frescas and de Lange, 2014), it is expected that the truncated proteins fail to efficiently accumulate at telomeres. In agreement, telomeric ChIP assays using the HA antibody on chromatin from 293T cells expressing the HA-tagged versions of TIN2 showed that the S186fs and L170fs proteins do not associate with telomeric DNA (Figure 3C–E). The E202fs protein may be slightly more proficient in telomeric association but the fraction of telomeric DNA recovered in the ChIP was not significantly increased compared to cells transfected with the empty vector. These data indicate that the truncated versions of TIN2 have lost the ability to function at telomeres.

**Telomeres are fully protected in cells heterozygous for c.604G > C or c.557del**

CRISPR/Cas9-mediated gene editing was used to knock in the c.557del and c.604G > C mutations in RPE1-hTERT cells deficient for Rb and p53 (Yang et al., 2017). The mutations were introduced using knock-in repair ssODN templates with the desired mutation, a mutated PAM, and a restriction enzyme recognition site used for screening of clonal cell lines (Figure 4—figure supplement 2). The CRISPR/Cas9 editing was designed to generate matched wild-type control clones with TIN2+ genes that were either unedited or edited with silent nucleotide changes (introduction of a restriction enzyme site and a mutated PAM). In addition, we targeted exon 1 of TIN2 to generate heterozygous KO clones (TIN2+/KO or +/-; Figure 4—figure supplement 3) and accompanying control clones. For each genotype, several clones with the desired alterations were isolated (Figure 4—figure supplement 4). The mutated clonal cell lines showed the same proliferation rate as the control clones (Figure 4—figure supplement 5A). CRISPR/Cas9 editing of RPE1 cells also yielded a viable clone homozygous for the c.604G > C mutation (Figure 4—figure supplement 6B). Although this clone does not represent the genotype of the patients, it is useful as a positive control in telomere dysfunction assays. Transcript analysis of the heterozygous and homozygous c.604G > C RPE1 clones confirmed expression of the c.604G > C II mRNA identified in patient samples (see Figure 2A,B) and identified the c.604G > C I transcript as an additional product from the mutated locus (Figure 4—figure supplement 1 and Figure 2B).

Clones heterozygous for the c.604G > C or c.557del mutation and the TIN2+/− clones had slightly lower TIN2 protein levels relative to the controls (Figure 4A,B). Based on telomeric chromatin immunoprecipitation (ChIP) and immunofluorescence (IF) analysis, cells heterozygous for the mutations retained TIN2, TRF1, TPP1, and POT1 at their telomeres, although the data do not exclude a moderate reduction in the association of these proteins with telomeres (Figure 4—figure supplement 5B–G). In contrast, the homozygous c.604G > C clone showed a complete absence of TIN2 in immunoblots and the presence of TIN2, TRF1, TPP1, and POT1 at telomeres was strongly reduced (Figure 4A,B and Figure 4—figure supplement 5E–G).

The extent to which the TIN2 mutations affected telomere protection was monitored via the telomere dysfunction induced foci (TIF) assay (Takai et al., 2003), which measures the accumulation of 53BP1 at telomeres. Clones with heterozygous c.557del or c.604G > C mutations had the same TIF response as the control cells (Figure 4C,D and Figure 4—figure supplement 6A). Similarly, the TIF response was not increased in the TIN2+/− clones compared to wild-type controls. In contrast, the homozygous c.604G > C clone showed obvious loss of telomere protection (Figure 4C,D and Figure 4—figure supplement 6A), likely due to the reduced telomeric association of POT1, which is required to prevent the activation of ATR signaling at human telomeres (Denchi and de Lange, 2007). These results indicate that one functional TIN2 gene is sufficient to sustain full telomere protection and that the truncated TIN2 proteins do not have a dominant negative effect on telomere protection.

Similarly, analysis of metaphase spreads showed that heterozygosity for the TIN2 mutations or the exon 1 KO allele did not induce a significant level of telomere dysfunction. Although cells carrying the homozygous c.604G > C mutation showed elevated levels of sister telomere associations and a low level of chromosome fusions, such aberrations were not significantly increased in the heterozygous clones relative to wild type (Figure 4E–G, Figure 4—figure supplement 6B,C). Thus, TINF2 is not haploinsufficient for telomere protection and the TINF2 mutations are unlikely to induce cancer-promoting genome rearrangements.
Excessive telomere elongation associated with c.604G > C and c.557del

Telomere length analysis in lymphocytes from three patients carrying the c.604G > C or c.557del mutations revealed a median telomere length above the 99th percentile as measured by Flow-FISH (Figure 1A and Figure 5—figure supplement 1A). Similarly, individuals with the TIN2 p.W198fs mutation showed telomeres that were approximately twofold longer based on qPCR (He et al., 2020). The presence of exceptionally long telomeres in the c.604G > C individuals was verified by...
**Figure 5.** Heterozygous TINF2 mutations induce telomere lengthening. (A) Telomeric Southern blot of MboI/AluI-digested genomic DNA from immortalized and primary patient cells (lymphocytes), normal lung fibroblasts (MRC5), and HeLa1.3 cells. Median telomere length (MTL) is indicated. (B) Telomeric Southern blot of MboI/AluI-digested genomic DNA from control clones and clones with heterozygous c.604G > C mutations at the indicated PDs. Telomere length changes are indicated and were calculated over 48 PDs. (C) Quantification of median telomere length changes for control cells

Figure 5 continued on next page
and cells with heterozygous c.604G > C mutations. Three cell lines per genotype were analyzed in two independent experiments (symbols denote the individual cell lines). (D) Telomeric Southern blot as in (B) for control clones and clones with heterozygous c.557del mutations. (E) Quantification of median telomere length changes for control cells and clones with heterozygous c.557del mutations as in (C). (F) Detection of telomeres in Mbol/Alu-digested genomic DNA from control clones and clones with heterozygous c.557del mutation probed under native conditions with a telomeric probe for the 3’ overhang. The change in MTL over 28 PDs is indicated. (G) Telomeric southern blot as in (B) for control cells and TIN2+/- cells. The indicated telomere length changes were calculated over 42 PDs. (H) Quantification of median telomere length changes for control cells and TIN2+/- cells as in C. (I) Telomeric southern blot of Mbol/Alu-digested genomic DNA from control and TIN2+/- hESCs. All clones were generated and propagated in parallel and telomere length was determined at 28 days after the CRISPR/Cas9 targeting. (J) Quantification of the median telomere length (as determined by blotting as in (I)) for control and heterozygous hESCs clones (control, n = 5; TIN2+/-KO, n = 4). Bar graphs in (C), (E), (H), and (J) show means ± SDs. P-values are based on unpaired t-test. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. ns, not significant. See also Figure 5—figure supplements 1–3.

The online version of this article includes the following figure supplement(s) for figure 5:

**Figure supplement 1.** Long telomeres in TINF2 c.604G > C and c.557del patients and hESC CRISPR/Cas9 editing.

**Figure supplement 2.** No evidence for increased telomere recombination in c.604G > C mutant and Tin2+/- cells.

**Figure supplement 3.** Mutant and control RPE1 clones show similar telomerase activity.

genomic blotting, showing that both primary and EBV-immortalized lymphocytes from two patients carried telomeres of ~13 kb (Figure 5A).

Consistent with the unusually long telomeres in the patients, telomere elongation was observed in RPE1 clones heterozygous for c.557del or c.604G > C (Figure 5B–F). For each genotype, three cell lines were tested over up to 3 months of propagation with the appropriate control cell lines cultured and analyzed in parallel. The change in telomere length with population doublings (PDs) was measured in two independent experiments for each clone. As expected, the initial telomere lengths show clonal variation as has been observed in other cell lines (Bryan et al., 1998; Takai et al., 2010). Comparison of the telomere elongation per PD between the control clones and the heterozygous clones showed that both the c.557del and the c.604G > C mutation resulted in a greater extension of the telomeres (Figure 5B–F). This was the case when the total telomeric DNA was detected in standard genomic blots and the same result was obtained when telomere length was evaluated based on hybridization of a probe to the 3’ overhang in native gels (Figure 5F). Similarly, cells heterozygous for the exon one truncation showed greater rates of telomere elongation and this phenotype was observed in RPE1 cells as well as in human embryonic stem cells (hESCs) heterozygous for a deletion of exons 4–7 (Figure 5G–J and Figure 5—figure supplement 1B,C). All RPE1 clones showed approximately the same telomerase activity (Figure 5—figure supplement 2). The observed telomere elongation is likely due to telomerase-mediated elongation because there was no evidence for increased telomere recombination in the cell lines (Figure 5—figure supplement 3), and the telomeres did not show the typical heterogeneous size of ALT telomeres (Figure 5). An effect of TIN2 on telomerase-mediated telomere elongation is consistent with prior data showing that a truncated TIN2 protein induced dramatic telomere elongation in cells expressing telomerase but had no effect in telomerase-negative cells (Kim et al., 1999). These data indicate that the TINF2 gene is haploinsufficient for telomere length control and explain the telomere elongation phenotype in the patients.

**Discussion**

These data reveal TINF2 as a haploinsufficient tumor suppressor gene. Inactivation of one TINF2 allele through truncation mutations results in inherited cancer predisposition with high penetrance and severity. The spectrum of cancers in the TINF2 families studied here is broad, including breast cancer, colorectal cancer, thyroid cancer, and melanoma, and several patients had multiple independent malignancies. Similarly, a recent report identified a TINF2 truncation mutation in a large family affected by thyroid cancer and melanoma (He et al., 2020). It is remarkable that inherited mutations in TINF2 can have two widely distinct outcomes. While the loss-of-function mutations described here cause cancer through aberrant telomere elongation, missense mutations in the DC patch of TINF2 cause bone-marrow failure syndromes that are due to excessive telomere shortening. These disparate outcomes reflect the dual role of TIN2, which uses its DC patch to promote telomere...
maintenance by telomerase, while keeping telomere length in check through its interaction with TRF1 and TPP1/POT1. Our genetic data underscore that telomere length at birth needs to be carefully controlled within a narrow range to prevent premature stem cell depletion on one hand and cancer on the other.

**Genetic evidence for the telomere tumor suppressor pathway**

It has proven difficult to test the idea that telomere shortening represents a tumor suppressor pathway. Apart from modeling in the mouse (Artandi and DePinho, 2000), evidence in favor of this decades-old concept is derived largely from indirect or in vitro observations (reviewed in Maciejowski and de Lange, 2017). The discovery of hTERT promoter mutations in familial melanoma and sporadic cancers argued that telomerase activation is a critical step in tumor progression (Horn et al., 2013; Huang et al., 2013; reviewed in Lorbeer and Hockemeyer, 2020). However, it did not definitively establish that telomerase is needed to subvert the telomere tumor suppression pathway. The requirement for telomerase activation during cancer progression could also be due to its presumed ability to heal broken chromosomes arising during periods of genome instability.

Cancer-predisposing mutations in the POT1 subunit of shelterin also did not inform on the telomere tumor suppressor pathway because they have two outcomes of potential relevance to cancer. On one hand, the altered POT1 alleles result in very long germline telomeres in the probands, consistent with the idea that telomere shortening curbs tumorigenesis (NCI DCEG Cancer Sequencing Working Group et al., 2014; Robles-Espinosa et al., 2014). On the other hand, the mutations were reported to induce genome instability (Ramsay et al., 2013; Pinzaru et al., 2016; Chen et al., 2017; Gu et al., 2017). Indeed, most reports concluded that the cancer predisposition associated with these POT1 alleles is due to genomic rearrangements. However, these studies largely relied on overexpression of mutant versions of POT1 and did not examine cells with the heterozygous POT1 mutations found in the patients.

The cancer-causing TINF2 mutations that create long germline telomeres without affecting telomere protection now remove the ambiguity. In the TINF2 cases affected by inherited cancer predisposition, it is extremely unlikely that genome instability contributes to tumorigenesis since we have not detected loss of telomere protection or genome instability in heterozygous cell lines whose genotype mimic the patient status. The simplest interpretation is that the patient’s frequent malignancies are due to a failure in the telomere tumor suppressor pathway. By extension, we argue that there is no need to invoke genome instability as a cancer-promoting aspect of the POT1 mutations in familial cancer. The data presented here argue that the telomere elongation phenotype associated with the POT1 mutations is sufficient to explain the higher incidence of cancer in these families.

According to our findings, exceptionally long telomeres can lead to cancer predisposition. Our conclusion is consistent with prior GWAS studies suggesting an effect of telomere length on cancer predisposition (Rode et al., 2016; Telomeres Mendelian Randomization Collaboration et al., 2017; reviewed in McNally et al., 2019). It is therefore pertinent to consider measuring telomere length in cancer-prone families lacking other genetic risk factors. Our findings also suggest that caution is warranted with regard to efforts to interfere with the telomere shortening program in healthy individuals (Harley et al., 2011).

**Telomere length homeostasis in vitro and in vivo**

The elongated telomeres associated with the inherited POT1 and TINF2 mutations now suggest that the telomere length homeostasis observed in cultured cells reflect aspects of telomere length control in the human germline. In vitro, TRF1, TIN2, and POT1 have been implicated as negative regulators of telomere length largely based on the telomere elongation phenotype of dominant negative alleles (van Steensel and de Lange, 1997; Kim et al., 1999; Loayza and De Lange, 2003). The role of TPP1 (which links POT1 to TIN2) is more complex because it acts to limit telomere extension through POT1 but also recruits telomerase to telomeres (Nandakumar et al., 2012; Zhong et al., 2012). How the shelterin subunits control telomerase activity in cis has remained opaque (reviewed in Hockemeyer and Collins, 2015). It is clear that the trimeric Ctc1, Stn1, Ten1 (CST) complex is required to control the length of human telomeres but how CST blocks telomerase is still unknown (Wan et al., 2009; Chen et al., 2012; Feng et al., 2017; Takai et al., 2016). The finding that cell culture systems reflect regulatory pathways observed in vivo should spur further in vitro experiments.
designed to illuminate how telomere length homeostasis is achieved. An important question to be
addressed is why TIN2 is haploinsufficient for telomere length control and which other shelterin com-
ponents show this phenotype. Shelterin components that are haploinsufficient for telomere length
control but not for telomere protection are of particular interest since loss-of-function mutations in
these genes could predispose to cancer.

When does TIN2 act as a tumor suppressor?

TINF2 mutations lead to unusually long telomeres in the peripheral blood lymphocytes of the
patients reported here. It is assumed that such long telomeres reflect the long telomeres present in
the bone marrow stem cells since the number of divisions separating bone marrow stem cells from
peripheral lymphocytes is too limited to allow the low level of telomerase in lymphocytes to extend
the telomeres substantially. If this assumption is correct, the patients are likely born with unusually
long telomeres in most of their stem cell compartments.

How could such long stem cell telomeres have originated? One possibility is that the TINF2 muta-
tions lead to extended telomeres in the parental germline that are then inherited by the affected
child. We argue that this scenario does not account for several observations. First, if long telomeres
inherited from one parent were the cause of the cancer predisposition, all children of an affected
parent would be equally predisposed to cancer. Our data and the co-segregation of the TINF2 p.
W198fs variant with cancer in one large family (He et al., 2020), argues that this is not the case. Sec-
ond, genomic blots indicate a single class of very long telomeres in the peripheral blood lympho-
cytes of adults with the TINF2 mutations. If these individuals had inherited long telomeres from one
parent and short telomeres from the other without further changes in telomere length (except for
the usual telomere attrition), the telomeres should reveal two size classes, one of which is in the nor-
mal range. Our genomic blots show that this is not the case. Finally, simple inheritance of long telo-
meres from one parent would not delay the onset of the Hayflick limit, which is determined by the
shortest telomeres in a clone. The normal-sized telomeres from the unaffected parent should allow
the Hayflick limit to protect against cancer regardless of the presence of longer telomeres from the
affected parent.

These considerations lead us to propose that the TINF2 mutations act by inappropriately elongat-
ing telomeres during early development. Importantly, such a process would elongate the normal
sized telomeres inherited from the unaffected parent, preventing the timely onset of the Hayflick
limit. Since telomerase is detectable in a number of embryonic tissues during the first and second tri-
mester (Wright et al., 1996), it is reasonable to assume that tens of cell divisions take place during
which the enzyme can elongate telomeres unless it is restrained by the telomere length homeostasis
pathway. We imagine that the TINF2 mutations exert their cancer-promoting effects in the first
weeks or months after fertilization, resulting not only in long telomeres in the germline but also in all
other stem cell compartments that are relevant to cancer development later in life. According to this
reasoning, TINF2 would be a tumor suppressor gene with a very specific window of opportunity,
exerting its effect early in development but not later.

Materials and methods

| Key resources table |
|---------------------|
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
| Cell line (H. sapiens) | 293T | ATCC | | |
| Cell line (H. sapiens) | hTERT-RPE1 p53/-/ Rb/-/ | Yang et al., 2017 | | |
| Cell line (H. sapiens) | hTERT-RPE1 p53/-/ Rb/+/604G > C.1 clone 1–3 m | This paper | Heterozygous for TINF2 c.604G > C |
| Cell line (H. sapiens) | hTERT-RPE1 p53/-/ Rb/+/604G > C.2 clone 2–23 m | This paper | Heterozygous for TINF2 c.604G > C |
| Cell line (H. sapiens) | hTERT-RPE1 p53/-/ Rb/+/604G > C.3 clone 1–21 m | This paper | Heterozygous for TINF2 c.604G > C |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ |- ctrl4 clone 1–4 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ |- ctrl5 clone 1–13 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ |- ctrl6 clone 5–8 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-557del.1 clone 1–9 m |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-557del.2 clone 1–14 m |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-557del.3 clone 2–17 m |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | ctrl1 clone 2–7 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | ctrl2 clone 2–8 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | ctrl3 clone 1–2 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-1 clone 1-1het   |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-2 clone 1-3het   |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-3 clone 2-4het   |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-1 ctrl1 clone 2–9 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-1 ctrl8 clone 3–2 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | hTERT-RPE1  | This paper          |             | Control cell line      |
|<Cell line (H. sapiens)            | p53-/- Rb-/ | +/-1 ctrl9 clone 1–4 c |             |                        |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC  | Lengner et al., 2010 | NIH stem cell registry number: 0079 | Wild-type |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 1B1 | This paper | +/- TINF2 Control cell line |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 3B4 | This paper | +/- TINF2 Control cell line |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 3C2 | This paper | +/- TINF2 Control cell line |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 5B1 | This paper | +/- TINF2 Control cell line |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 3B3 | This paper | +/- TINF2 |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 4B4 | This paper | +/- TINF2 |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 5A4 | This paper | +/- TINF2 |            |
|<Cell line (H. sapiens)            |            |                     |             |                        |
|<Cell line (H. sapiens)            | WIBR3 hESC 5B3 | This paper | +/- TINF2 |            |
|<Anti-hTIN2                        | Ye and de Lange, 2004 | #864 |                            |            |
|<Anti-αTubulin                     | Sigma | GTUB88 |                                |            |
|<Anti-Myc                          | Cell signaling | 9B11 |                                |            |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|-------------|------------------------|
| Anti-HA                           | Abcam       |                    | Ab9110      |                        |
| Anti-53BP1                         | Abcam       |                    | ab175933    |                        |
| Cy3-OO-(TTAGGG)$_3$                | PNA bio     |                    |             | Telomere probe         |
| FITC-OO-(CCCTAA)$_3$               | PNA bio     |                    |             | Telomere probe         |
| Alexa Fluor 647-OO-(TTAGGG)$_3$   | PNA bio     |                    |             | Telomere probe         |
| CENPB-AF488                        | PNA bio     |                    | F3004       | Centromere probe       |

No statistical methods were used to predetermine sample size. Key resources are listed in the key resource table.

**Patient selection**
As part of routine diagnostic procedure, whole exome sequencing and subsequent cancer predisposition panel analysis was performed on patients who developed multiple malignancies or had a striking family history of cancer. The four index patients reported in this study were sequenced between 2014 and 2019 and were part of a total cohort of 446 patients referred for this diagnostic procedure. Whole exome sequencing was performed with relevant clinical quality accreditations and consent procedures as approved by the IRB equivalent (Medisch Ethische Toetsingscommissie) of the Radboud University Medical Center. All participants (four probands and two affected relatives) provided written informed consent for publication of their data.

**Whole exome sequencing**
Genomic DNA was isolated from whole blood. The experimental workflow of all exomes was performed at BGI Europe (Beijing Genome Institute Europe, Copenhagen, Denmark). Exonic regions were enriched using the Agilent (Agilent Technologies, CA, USA) SureSelect V4 ($n = 85$) or V5 ($n = 169$) kit and sequenced using an Illumina Hiseq (Illumina, CA, USA) sequencer with 101 bp paired end reads to a median coverage of >75 x. Sequenced reads were mapped to the hg19 reference genome using the mapping algorithm from BWA (Li and Durbin, 2010) (version 0.5.9-r16) and called by the GATK unified genotyper (McKenna et al., 2010) (version 3.2–2). All variants were annotated using an in-house pipeline for exome analysis containing variant and gene-specific information. This information includes the variant population frequencies from >5000 in-house whole exome analyses performed (Lelieveld et al., 2016).

Whole genome sequencing was performed on tumor DNA as described previously (NTHL1 study group et al., 2020) using the SureSelectXT Human All Exon V6 enrichment kit (Agilent Technologies, CA, USA) on a NextSeq500 sequencing platform (Illumina, CA, USA). Trimmed NextSeq 500 sequencing reads were aligned to hg19 by using BWA-MEM, and duplicates were flagged by using Picard Tools, version 1.90. Variants were called with Mutect2 (GATK version 4.1.0.0), with matched germline samples; variant filtering was performed as described (NTHL1 study group et al., 2020). All variants were annotated using an in-house annotation pipeline and driver genes were selected based in the COSMIC cancer gene census.

**Exome variant interpretation**
For the gene panel analysis, a bioinformatic in silico filter was applied to select for variants affecting the known cancer predisposition genes. This gene panel consisted of 114 established (OMIM) cancer predisposition genes in 2013, expanding to 232 genes in 2019. All subsequent versions of this panel included the TINF2 gene, because of its role in cancer predisposition in dyskeratosis congenita. Variants were filtered for coding, non-synonymous variants with population frequencies below 1% in our in-house database and evaluated regarding their possible pathogenicity. The latter was performed using population frequencies, nucleotide conservation scores (PhyloP), and in silico pathogenicity predictions (SIFT, Polyphen2, Mutation Taster).

Schmutz et al. eLife 2020;9:e61235. DOI: https://doi.org/10.7554/eLife.61235
Transcript analysis

For transcript analysis in c.604G > C mutant and control cells, RNA isolation (RNeasy Mini kit, Qiagen) and cDNA synthesis (Superscript IV Reverse Transcriptase, ThermoFisher) was performed according to standard protocols. TINF2 transcripts were amplified, separated according to size, cloned into pCR-Topo and analyzed by Sanger Sequencing. Primers used:

\[
\begin{align*}
\text{TINF2\_transcriptfw} & \quad \text{TINF2-exon2} & 5\:'-TCCTGAAAGCCCTGAATCAC-3\:' \\
\text{TINF2\_transcriptrv} & \quad \text{TINF2-exon6} & 5\:'-GGGTCTGGCATGGACTCTTA-3\:' 
\end{align*}
\]

Cell culture

293T cells (ATCC; not further authenticated) were grown in DMEM supplemented with 10% bovine calf serum (Hyclone), 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.1 mM nonessential amino acids. hTERT-RPE1 p53-/- Rb-/- cells (Yang et al., 2017) were generated using RPE1 cells from the ATCC (not further authenticated) and cultured in DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum (GIBCO), 100 U/ml penicillin (Sigma) and 0.1 mg/ml streptomycin (Sigma). Stem cell culture was performed as described previously (Chiba et al., 2015) using WIBR#3 hESCs (NIH stem cell registry number: 0079; not further authenticated Lengner et al., 2010). All cell lines were free of mycoplasma.

Expression vectors

Vectors expressing N-terminally Flag-(HA)\textsuperscript{2} tagged TIN2 and N-terminally Myc-tagged TRF1, TRF2, and TPP1 were as previously described (Smogorzewska and de Lange, 2002; Frescas and de Lange, 2014). Flag-(HA)\textsubscript{2}-TIN2 S186fs was cloned by site-directed mutagenesis (QuikChange II XL, Agilent Technologies). For the cloning of Flag-(HA)\textsubscript{2}-TIN2 L170fs and Flag-(HA)\textsubscript{2}-TIN2 E202fs, mutant transcripts were amplified from the cDNA recovered from c.604G > C mutant cells (604G > C homozyg) and the wild-type fragment in pLPC-Flag-(HA)\textsubscript{2}-Tin2 was replaced with the respective mutant BamH/I/Bpl fragments.

Co-immunoprecipitation and immunoblotting

For co-immunoprecipitation assays, Flag-(HA)\textsubscript{2} tagged TIN2 proteins were co-expressed with Myc-tagged TRF1, TRF2, and TPP1 in 293T cells. Cells were collected 36–48 hr after calcium phosphate transfection as previously described (Takai et al., 2016). Lysates were diluted to lower the NaCl concentration to 200 mM for TPP1 and TRF1 and to 100 mM for TRF2 immunoprecipitations. HA-tagged TIN2 was precipitated using aHA agarose beads for 2 hr at 4°C, beads were washed with lysis buffer and PBS, proteins were eluted with Laemmli loading buffer and analyzed by immunoblotting using aHA antibody (HA.11, Covance) for TIN2 and Myc antibody (9B11, Cell signaling) for co-immunoprecipitated TRF1, TRF2, and TPP1. For TIN2 immunoblots, whole-cell lysates were prepared by lysis of cells in buffer C (20 mM Hepes-KOH pH 7.9, 0.42 M KCl, 25% glycerol, 0.1 mM EDTA, 5 mM MgCl\textsubscript{2}, 0.2% NP-40, complete protease inhibitor cocktail), quantified by Biuret protein assay and immunoblotted using antibodies for human TIN2 (#864) and γ tubulin (GTU88, Sigma).

Telomeric ChIP

Telomeric ChIP was performed as previously described (Loayza and De Lange, 2003). Telomeric DNA associated with shelterin proteins was immunoprecipitated with the following crude sera or purified antibodies: crude rabbit TRF1 (#371), crude rabbit TIN2 (#865), crude rabbit TPP1 (#1151), POT1 (Abcam, ab123784), anti-HA (Abcam, ab9110) and protein G magnetic beads (Cell signaling). For ChIP of exogenously introduced TIN2 alleles, 293T cells were transfected by calcium phosphate transfection, and crosslinked and harvested 36–48 hr after transfection.

CRISPR/Cas9-mediated targeting of TINF2 in RPE-1 cells

Clonal cell lines with targeted TINF2 alleles were generated using pU6- (BbsI)-Cbh-Cas9-T2a-mCherry (Chu et al., 2015) that allows co-expression of sgRNA and Cas9 linked to mCherry via the T2A peptide. For the knock-in of TINF2 mutations, the Cas9-sgRNA expression vector (TINF2 exon5, sgRNA1 or sgRNA2) was delivered together with a 1:1 mix of the appropriate donor oligonucleotides (ssODN) by electroporation (Lonza). mCherry-positive cells were selected by single-cell sorting.
Clones were screened by restriction enzyme digestion of PCR products and editing was verified by Sanger sequencing of Topo-cloned PCR products. For the generation of TINF2+/- cells, Cas9-sgRNA (TINF2exon1, sgRNA-3) was introduced by electroporation, mCherry-positive targeted cells were selected by single cell sorting. Clones were screened by Sanger sequencing of PCR products for introduction of mono-allelic indels creating frame-shift mutations in exon 1.

sgRNA oligonucleotides were purchased from ThermoFisher and cloned into BbsI-digested expression vector. The sequences are: sgRNA-1 5’-TTGTCTCCAGGCAAGAGAAG-(PAM)-3’; sgRNA-2 5’-GACAATATGGTGAGCGAGTCTACTACCTTTCTTCTTGAGACAGAAATAACAATGACATGGGTCAGCTTTCAGAGTGGAGGTTAGTGTTTAGC-3’; c.557del-control 5’-CAGCTTCAGGATGTGCTGAGTTGGATGCAGCCTGGAGTCTCTATCACCTCTTCTGAGACAGTGGAGCAGCTTTCAGAGTGGAGGTTAGTGTTTAGCCTGAGACCTTTTGAGGCAGTCCACTGGAATAGTT-3’.

CRISPR/Cas9-mediated targeting of TINF2 in hESCs

Stem cell culture and editing experiments were performed as described previously (Chiba et al., 2015). To delete exons 4–7 of TINF2 in WIBR#3 hESCs (NIH stem cell registry number: 0079; Lengner et al., 2010), cells were co-electroporated with 15 ug of two PX330 Cas9 plasmids (Cong et al., 2013), containing guide sequences 5’-TGTTCAAGTTCCTACAGCAG-3’ and 5’-CC TGACTCAGACTACCTACC-3’, respectively, and 7.5 μg of a GFP plasmid. Targeting was confirmed by PCR on genomic DNA using fw primer 5’-GGCCACTAACCCACTTTTGA-3’ and rev primer 5’-TGGCCATTTTCTTCCTCATCACCCTTGAGACAGCTTTCAGAGTGGAGGTTAGTGTTTAGCCTGAGACCTTTTGAGGCAGTCCACTGGAATAGTT-3’. Expected product sizes are 1275 bp for wild-type band and 218 bp for the exons 4–7 deletion.

IF-FISH

For immunofluorescence in combination with telomeric FISH (IF-FISH), cells grown on coverslips to sub-confluence and were fixed in MeOH for 10 min at −20°C. IF-FISH was carried out as previously described (Takai et al., 2003). The following affinity purified antibodies were used for IF: rabbit TRF2 (#647), rabbit TRF1 (#371), rabbit TIN2 2 (#864), rabbit 53BP1 (Abcam ab175933). Telomeric DNA was detected with FITC-OO-(CCCTAA)3 PNA probe. Images were captured on a DeltaVision microscope (Applied Precision) equipped with a cooled charge-coupled device camera (DV Elite CMOS Camera), a PlanApo 60 × 1.42 NA objective (Olympus America), and SoftWoRx software.

FISH and CO-FISH on metaphase chromosomes

Telomeric FISH and CO-FISH were conducted as previously described (van Steensel et al., 1998; Celli et al., 2006) using Alexa Fluor 647-OO-(TTAGGG)3, Cy3-OO-(TTAGGG)three or FITC-OO-(CCCTAA)three and a centromere probe (PNA Bio). Images were captured using a DeltaVision microscope (Applied Precision) equipped with a cooled charge-coupled device camera (DV Elite CMOS Camera) and a PlanApo 60 × 1.42 NA objective (Olympus America), and controlled by and SoftWoRx software.

Flow-FISH

Flow-FISH analysis was performed by RepeatDX (Aachen, Germany) on DNA from patient peripheral blood lymphocytes according to standard protocols (Alter et al., 2007).
Telomere length analysis

For analysis of telomere length, cells were grown for 70 PDs and samples were harvested periodically by trypsinization, washed with 1x PBS, pelleted and frozen until further analysis. Genomic DNA was prepared as previously described (de Lange et al., 1990). DNA for telomere length analysis was digested with MboI and AluI, quantified using Hoechst 33259 fluorometry and 0.5–1 μg was run on 0.7% agarose gels in 0.5x TBE. The DNA was depurinated, denatured, and neutralized and transferred onto membrane as previously described (de Lange et al., 1990). Blots were probed for telomeres using the Sty11 probe (de Lange, 1992). Alternatively, telomere length was evaluated based on the hybridization of a probe to the 3’ overhang in native gels. For this, gels were dried and probed with an end-labeled (CCCTAA)_A as previously described (Karlseder et al., 2002). Gels and membranes were exposed to Phosphorimager screens and quantified with Fiji.

TRAP assay

TRAP assay was performed according to manufacturer’s descriptions (TRAPeze Telomerase Detection Kit, EMD Millipore). Reaction products were run on a native polyacrylamide gel and stained with ethidium bromide.

Acknowledgements

We thank the members of the de Lange lab for helpful discussion. John Zinder is thanked for generating the structural representation of the TIN2 truncations. Research reported in this publication was supported by grants from the NCI (R35CA210036), the Breast Cancer Research Foundation, and the Melanoma Research Alliance (MRA 577521) to T.d.L. T.d.L. is an American Cancer Society Rose Zarucki Trust Research Professor. D.H. is a Chan Zuckerberg Biohub Investigator, a Pew-Stewart Scholar for Cancer Research supported by the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. This research is supported by grants to D.H. from the Siebel Stem Cell Institute, the NIH (R01-CA196884), the D.O.D. (W81XWH-19-1-0586), and a Research Scholar Grants from the American Cancer Society (133396-RSG-19-029-01-DMC).

Additional information

Competing interests

Titia de Lange: Member of the SAB of Calico Life Sciences LLC. The other authors declare that no competing interests exist.

Funding

| Funder                                      | Grant reference number     | Author            |
|---------------------------------------------|----------------------------|-------------------|
| NIH                                         | R01-CA196884               | Dirk Hockemeyer   |
| U.S. Department of Defense                  | W81XWH-19-1-0586           | Dirk Hockemeyer   |
| American Cancer Society                     | 133396-RSG-19-029-01-DMC   | Dirk Hockemeyer   |
| National Cancer Institute                   | R35CA210036                | Titia de Lange    |
| Melanoma Research Alliance                 | 577521                     | Titia de Lange    |
| American Cancer Society Rose Zarucki Trust | Rose Zarucki Trust Research Professor | Titia de Lange |
| Breast Cancer Research Foundation          |                            | Titia de Lange    |
| Siebel Stem Cell Institute                  |                            | Dirk Hockemeyer   |
| Pew Charitable Trusts                       |                            | Dirk Hockemeyer   |
| Alexander and Margaret Stewart Trust        |                            | Dirk Hockemeyer   |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

Isabelle Schmutz, Conceptualization, Data curation, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing; Arjen R Mensenkamp, Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing - review and editing; Kaori K Takai, Data curation, Investigation; Maaike Haadsma, Liesbeth Spruijt, Data curation; Richarda M de Voer, Data curation, Investigation, Writing - review and editing; Seunga Sara Choo, Emma J van Grinsven, Investigation; Franziska K Lorbeer, Investigation, Writing - review and editing; Dirk Hockemeyer, Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing; Marjolijn CJ Jongmans, Conceptualization, Supervision, Investigation, Writing - review and editing; Titia de Lange, Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing.

**Author ORCIDs**

Isabelle Schmutz [https://orcid.org/0000-0001-7193-3922](https://orcid.org/0000-0001-7193-3922)
Arjen R Mensenkamp [https://orcid.org/0000-0003-3805-877X](https://orcid.org/0000-0003-3805-877X)
Franziska K Lorbeer [http://orcid.org/0000-0002-3152-6852](http://orcid.org/0000-0002-3152-6852)
Dirk Hockemeyer [http://orcid.org/0000-0002-5598-5092](http://orcid.org/0000-0002-5598-5092)
Titia de Lange [http://orcid.org/0000-0002-9267-367X](http://orcid.org/0000-0002-9267-367X)

**Ethics**

Human subjects: This study was performed in accordance with the local Institutional Review Board and all participants (four probands and two affected relatives) provided written informed consent for publication of their data.

**Decision letter and Author response**

Decision letter [https://doi.org/10.7554/eLife.61235.sa1](https://doi.org/10.7554/eLife.61235.sa1)
Author response [https://doi.org/10.7554/eLife.61235.sa2](https://doi.org/10.7554/eLife.61235.sa2)

**Additional files**

**Supplementary files**

- Supplementary file 1. Uncropped images of immunoblots and telomere blots shown in the main figures.
- Supplementary file 2. Uncropped images of immunoblots and telomere blots shown in the main figures.
- Supplementary file 3. Uncropped images of immunoblots and telomere blots shown in the main figures.
- Supplementary file 4. p-Values and summary statistics for key data.
- Transparent reporting form

**Data availability**

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided in the Supplementary files.
References

Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, Peters JA, Giri N, Lansdorp PM. 2007. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110:1439–1447. DOI: https://doi.org/10.1182/blood-2007-02-075598, PMID: 17468339

Artandi SE, DePinho RA. 2000. Mice without telomerase: what can they teach us about human Cancer? Nature Medicine 6:852–855. DOI: https://doi.org/10.1038/78595, PMID: 10932211

Bodnar AG, Ouellette M, Frolikis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352. DOI: https://doi.org/10.1126/science.279.5349.349, PMID: 9454332

Bryan TM, Englezou A, Dunham MA, Reddel RR. 1998. Telomere Length Dynamics in Telomerase-Positive Immortal Human Cell Populations. Experimental Cell Research 239:370–378. DOI: https://doi.org/10.1006/excr.1997.3907

Celi GB, Denchi EL, de Lange T. 2006. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nature Cell Biology 8:885–890. DOI: https://doi.org/10.1038/ncb1444, PMID: 16845382

Chen LY, Redon S, Lingner J. 2012. The human CST complex is a terminator of telomerase activity. Nature 488:540–544. DOI: https://doi.org/10.1038/nature11269, PMID: 22763445

Chen C, Gu P, Wu J, Chen X, Niu S, Sun H, Wu L, Li N, Peng J, Shi S, Fan C, Huang M, Wong CC, Gong Q, Kumar-Sinha C, Zhang R, PusztaI L, Rai R, Chang S, Lei M. 2017. Structural insights into POF1-TTF1 interaction and POF1 C-terminal mutations in human Cancer. Nature Communications 8:14929. DOI: https://doi.org/10.1038/s41467-018-05477-9, PMID: 28393832

Chikaib, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. 2015. Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife 4:e07918. DOI: https://doi.org/10.7554/eLife.07918

Chu VT, Weber T, Wefer B, Wurst W, Sander S, Rajewsky K, Kuhn R. 2015. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nature Biotechnology 33:543–548. DOI: https://doi.org/10.1038/nbt.3198, PMID: 25803306

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. DOI: https://doi.org/10.1126/science.1231143, PMID: 23287718

de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, Varmus HE. 1990. Structure and variability of human chromosome ends. Molecular and Cellular Biology 10:518–527. DOI: https://doi.org/10.1128/MCB.10.2.518, PMID: 2300052

de Lange T. 1992. Human telomeres are attached to the nuclear matrix. The EMBO Journal 11:717–724. DOI: https://doi.org/10.1002/j.1460-2075.1992.tb05104.x, PMID: 1537344

de Lange T. 2018. Shelterin-Mediated telomere protection. Annual Review of Genetics 52:223–247. DOI: https://doi.org/10.1146/annurev-genet-032918-021921, PMID: 30208292

Denchi EL, de Lange T. 2007. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448:1068–1071. DOI: https://doi.org/10.1038/nature06065, PMID: 17687332

Feng X, Hsu S-J, Kasbek C, Chaiken M, Price CM. 2017. CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance. Nucleic Acids Research 45:4281–4293. DOI: https://doi.org/10.1093/nar/gkx125

Frescas D, de Lange T. 2014. TRF2-tethered TIN2 can mediate telomere protection by TP73/POT1. Molecular and Cellular Biology 34:1349–1362. DOI: https://doi.org/10.1128/MCB.01052-13, PMID: 24469404

Garvin MMV, Riedy CA, Houck NR, Charter JS, Walker W, Forsyth JP, Audas TN, Venditi C, Pagel M, Shay JW, Wright WE. 2011. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 10:761–768. DOI: https://doi.org/10.1111/j.1474-9726.2011.00718.x

Gong Y, Stock AJ, Liu Y. 2020. The enigma of excessively long telomeres in Cancer: lessons learned from rare human POT1 variants. Current Opinion in Genetics & Development 60:48–55. DOI: https://doi.org/10.1016/j.gde.2020.02.002, PMID: 32155570

Gu P, Wang Y, Bisht KK, Wu L, Lukova L, Smith EM, Xiao Y, Bailey SM, Lei M, Nandakumar J, Chang S. 2017. Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis. Oncogene 36:1939–1951. DOI: https://doi.org/10.1038/onc.2016.405, PMID: 27869160

Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. 1999. Creation of human tumour cells with defined genetic elements. Nature 400:464–468. DOI: https://doi.org/10.1038/22780, PMID: 10440377

Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460. DOI: https://doi.org/10.1038/345458a0, PMID: 2342578

Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM. 2011. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Research 14:45–56. DOI: https://doi.org/10.1089/rej.2010.1085, PMID: 20822369

Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866–868. DOI: https://doi.org/10.1038/346866a0, PMID: 2392154

He H, Li W, Comiskey DF, Liyanarachchi S, Nieminen TT, Wang Y, DeLap KE, Brock P, de la Chapelle A. 2020. A truncating germline mutation of TINF2 in Individuals with Thyroid Cancer or Melanoma Results in Longer Telomeres. Thyroid 30:204–213. DOI: https://doi.org/10.1089/thy.2019.0156, PMID: 31928178
Hemann MT, Strong MA, Hao LY, Greider CW. 2001. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell* **107**:67–77. DOI: https://doi.org/10.1016/S0092-8674(01)00504-9, PMID: 11595186

Hockemeyer D, Collins K. 2015. Control of telomerase action at human telomeres. *Nature Structural & Molecular Biology* **22**:848–852. DOI: https://doi.org/10.1038/nsmb.3083, PMID: 26381518

Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. 2013. TERT promoter mutations in familial and sporadic melanoma. *Science* **339**:959–961. DOI: https://doi.org/10.1126/science.1230062, PMID: 23348503

Hu C, Rai R, Huang C, Broton C, Long J, Xu Y, Xue J, Lei M, Chang S, Chen Y. 2017. Structural and functional analyses of the mammalian TIN2-TP1-TRF2 telomeric complex. *Cell Research* **27**:1485–1502. DOI: https://doi.org/10.1038/cr.2017.144, PMID: 29160297

Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Giarraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. *Science* **339**:957–959. DOI: https://doi.org/10.1126/science.1229259, PMID: 23348506

Huffman KE, Levene SD, Tesmer VM, Shay JW, Wright WE. 2000. Telomere shortening is proportional to the size of the G-rich telomeric 3’-overhang. *Journal of Biological Chemistry* **275**:19719–19722. DOI: https://doi.org/10.1074/jbc.M002843200, PMID: 10787419

Karseder J, Smogorzewska A, de Lange T. 2002. Senescence induced by altered telomere state, not telomere loss. *Science* **295**:2446–2449. DOI: https://doi.org/10.1126/science.1069523, PMID: 11923537

Kim S-ho, Kaminker P, Campisi J. 1999. TIN2, a new regulator of telomere length in human cells. *Nature Genetics* **23**:405–412. DOI: https://doi.org/10.1038/70508

Kipling D, Cooke HJ. 1990. Hypervariable ultra-long telomeres in mice. *Nature* **347**:400–402. DOI: https://doi.org/10.1038/347064a0, PMID: 2170845

Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P, de Vries BBA, Willemsen MH, Kleefstra T, Löhner K, Vreeburg M, Stevens SJC, van der Burgt I, Bongers EMHF, Stegmann APA, Rump P, Rinne T, Nelen MR, Veltman JA, Vissers LELM, et al. 2016. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nature Neuroscience* **19**:1194–1196. DOI: https://doi.org/10.1038/nn.4352

Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Woldstead GG, Alagappan R, Frampton GM, Xu P, Muffat J, Santagata S, Powers D, Barrett CB, Young RA, Lee JT, Jaenisch R, Mitalipova M. 2010. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. *Cell* **141**:872–883. DOI: https://doi.org/10.1016/j.cell.2010.04.010, PMID: 20471072

Li H, Durbin R. 2010. Fast and accurate long-read minkowski transform with Burrows-Wheeler transform. *Bioinformatics* **26**:589–595. DOI: https://doi.org/10.1093/bioinformatics/btp698, PMID: 20800505

Loayza D, De Lange T. 2003. POT1 as a terminal transducer of TRF1 telomere length control. *Nature* **423**:1013–1018. DOI: https://doi.org/10.1038/nature1688, PMID: 12768206

Lorbeer FK, Hockemeyer D. 2020. TERT promoter mutations and telomeres during tumorigenesis. Current Opinion in Genetics & Development **60**:56–62. DOI: https://doi.org/10.1016/j.gde.2020.02.001, PMID: 32163830

Maciejewski J, de Lange T. 2017. Telomeres in Cancer: tumour suppression and genome instability. *Nature Reviews Molecular Cell Biology* **18**:175–186. DOI: https://doi.org/10.1038/nrm.2016.171, PMID: 28096526

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research* **20**:1297–1303. DOI: https://doi.org/10.1101/gr.107524.110, PMID: 20644199

McNally EJ, Luncsford PJ, Armianios M. 2019. Long telomeres and Cancer risk: the price of cellular immortality. *Journal of Clinical Investigation* **129**:3474–3481. DOI: https://doi.org/10.1172/JCI120851, PMID: 31380804

Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR. 2012. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. *Nature* **492**:285–289. DOI: https://doi.org/10.1038/492285a, PMID: 23013865

NCCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, French Familial Melanoma Study Group, Shi J, Yang XR, Baliew B, Rotunno M, Calista D, Fargnoli MC, Garabaya C, Bressac-de Paillerets B, Nagore E, Avril MF, Cullen M, Wang Z, Zhang X, Bruno W, Pastorino L, Queirolo P, Banulis-Roca J, Garcia-Casado Z, et al. 2014. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nature Genetics* **46**:482–486. DOI: https://doi.org/10.1038/ng.2941, PMID: 24868486

NTHL1 study group, Elsayed FA, Grollemann JE, Ragunathan A, Buchanan DD, van Wezel T, de Voer RM. 2020. Monolelalic NTHL1 loss of function variants and risk of polyposis and colorectal Cancer. *Gastroenterology* **5085**:35113. DOI: https://doi.org/10.1053/j.gastro.2020.08.042

Pinzaru AM, Horn RA, Beal A, Phillips AF, Ni E, Cardozo T, Nair N, Choi J, Wuttke DS, Sfeir A, Denchi EL. 2016. Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis. *Cell Reports* **15**:2170–2184. DOI: https://doi.org/10.1016/j.crep.2016.05.008, PMID: 27239034

Ramsay AJ, Quesada V, Foronda M, Conde L, Martínez-Trillo s A, Villamor N, Rodríguez D, Kwarciak A, Garabaya C, Gallardo M, López-Guerra M, López-Guillermo A, Puente XS, Blasco MA, Campo E, López-Otin C. 2013. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. *Nature Genetics* **45**:526–530. DOI: https://doi.org/10.1038/ng.2584, PMID: 23502782

Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffin JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin Schmutz et al. *eLife* 2020;9:e61235. DOI: https://doi.org/10.7554/eLife.61235
NG, Liu JZ, Choi J, et al. 2014. POT1 loss-of-function variants predispose to familial melanoma. Nature Genetics 46:478–481. DOI: https://doi.org/10.1038/ng.2947

Rode L, Nordestgaard BG, Bojesen SE. 2016. Long telomeres and Cancer risk among 95 568 individuals from the general population. International Journal of Epidemiology 45:1634–1643. DOI: https://doi.org/10.1093/ije/dyw179, PMID: 27498151

Savage SA, Giri N, Baelflocher GM, Orr N, Lansdorp PM, Alter BP. 2008. TINF2, a Component of the Shelterin Telomere Protection Complex, Is Mutated in Dyskeratosis Congenita. The American Journal of Human Genetics 82:501–509. DOI: https://doi.org/10.1016/j.ajhg.2007.10.004

Savage SA, Bertuch AA. 2010. The genetics and clinical manifestations of telomere biology disorders. Genetics in Medicine 12:753–764. DOI: https://doi.org/10.1097/GIM.0b013e3181f415b5, PMID: 21189492

Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human Cancer. European Journal of Cancer 33: 787–791. DOI: https://doi.org/10.1016/S0959-8049(97)00062-2, PMID: 9282118

Shay JW, Wright WE. 2000. Hayflick, his limit, and cellular ageing. Nature Reviews Molecular Cell Biology 1:72–76. DOI: https://doi.org/10.1038/35036093, PMID: 11413492

Smogorzewska A, de Lange T. 2002. Different telomere damage signaling pathways in human and mouse cells. The EMBO Journal 21:4338–4348. DOI: https://doi.org/10.1093/emboj/cdf433, PMID: 12169636

Tabeske MA, Sealey DC, Dorrens J, Tayade C, Betts DH, Harrington L. 2012. Long telomeres bypass the requirement for telomere maintenance in human tumorigenesis. Cell Reports 1:91–98. DOI: https://doi.org/10.1016/j.celrep.2011.12.004

Takai H, Smogorzewska A, de Lange T. 2003. DNA damage foci at dysfunctional telomeres. Current Biology 13: 1549–1556. DOI: https://doi.org/10.1016/S0960-9822(03)00542-6, PMID: 12956959

Takai KK, Hooper S, Blackwood S, Gandhi R, de Lange T. 2010. In vivo stoichiometry of shelterin components. The Journal of Biological Chemistry 285:1457–1467. DOI: https://doi.org/10.1074/jbc.M109.038026, PMID: 19864690

Takah H, Jenkinson E, Kabir S, Babul-Hirji R, Najm-Tehrani N, Chitayat DA, Crow JY, de Lange T. 2016. A POT1 mutation implicates defective telomere end fill-in and telomere truncations in coats plus. Genes & Development 30:812–826. DOI: https://doi.org/10.1101/gad.276873.115, PMID: 27013236

Telomeres Mendelian Randomization Collaboration, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Curian KM, Pooley KA, Eeles RA, Lee JE, Fang S, et al. 2017. Association between telomere length and risk of Cancer and Non-Neoplastic diseases: a mendelian randomization study. JAMA Oncology 3:636–651. DOI: https://doi.org/10.1001/jamaoncol.2016.5945, PMID: 28241208

van Steensel B, Smogorzewska A, de Lange T. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell 92:401–413. DOI: https://doi.org/10.1016/S0092-8674(00)80932-0, PMID: 9476899

van Steensel B, de Lange T. 1997. Control of telomere length by the human telomeric protein TRF1. Nature 385: 740–743. DOI: https://doi.org/10.1038/385740a0, PMID: 9034193

Walne AJ, Vulliamy T, Beswick R, Kirwan M, Doki A. 2008. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 112:3594–3600. DOI: https://doi.org/10.1182/blood-2008-05-153445, PMID: 18669893

Wan M, Qin J, Songyang Z, Liu D. 2009. OB Fold-containing Protein 1 (OBFC1), a Human Homolog of Yeast Dyw179, Associates with TPP1 and Is Implicated in Telomere Length Regulation. Journal of Biological Chemistry 284:26725–26731. DOI: https://doi.org/10.1074/jbc.M109.021105

Wright WE, Patiyszek MA, Rainey WE, Byrd W, Shay JW. 1996. Telomerase activity in human germline and embryonic tissues and cells. Developmental Genetics 17:183–179. DOI: https://doi.org/10.1002/dvg.10701520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3, PMID: 8934879

Yang Z, Maciejowski J, de Lange T. 2017. Nuclear envelope rupture is enhanced by loss of p53 or rb. Molecular Cancer Research 15:1579–1586. DOI: https://doi.org/10.1158/1541-7786.MCR-17-0084, PMID: 28811362

Ye JZ, de Lange T. 2004. TIN2 is a tankyrase 1 PARP modulator in the TRF1 telomere length control complex. Nature Genetics 36:618–623. DOI: https://doi.org/10.1038/ng1360, PMID: 15133513

Zhong FL, Batista LF, Freund A, Pech MF, Venteicher AS, Artandi SE. 2012. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell 100:481–494. DOI: https://doi.org/10.1016/j.cell.2012.07.012, PMID: 22863003

Zou Y, Šefír A, Gryaznov SM, Shaye JW, Wright WE. 2004. Does a sentinel or a subset of short telomeres determine replicative senescence? Molecular Biology of the Cell 15:3709–3718. DOI: https://doi.org/10.1091/mbc.e04-03-0207, PMID: 15181152